Technology Quarterly | Next-generation medicine
CRISPR could yet save millions of lives. Here’s how
Gene-editing medicines have had a rocky start. But there is cause for optimism
|7 min read
FOR 20 YEARS Tamani Harris lived a life of pain. She was born with sickle-cell disease. Her red blood cells, made flat and stiff by a mutant version of haemoglobin, struggled to move smoothly through her blood vessels. Several times a month she would have a “crisis” where her cells got stuck somewhere in her body, causing excruciating pain. She needed strong opioids and often blood transfusions to recover. She had accepted that she might die young.
This article appeared in the Technology Quarterly section of the print edition under the headline “Not yet a cure-all”
From the March 1st 2025 edition
Discover stories from this section and more in the list of contents
Explore the edition